title: A case of acquired Fanconi syndrome induced by zoledronic acid.
abstract: A 61-year-old woman with metastatic breast cancer was diagnosed as having acquired Fanconi syndrome. In this case, the cause of this syndrome was most likely zoledronic acid (Zometa), which had been infused intravenously at a dose of 4 mg over 15 minutes weekly because of malignancy-associated hypercalcemia. Zoledronic acid is nephrotoxic and may induce severe tubular dysfunction, which can cause development of Fanconi syndrome. Therefore, close monitoring of proximal tubular function is recommended during therapy with zoledronic acid, especially when frequent administration of zoledronic acid is needed.
authors.affiliation: Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan. yosinami-te@mc.pref.osaka.jp
authors.forename: Tetsuhiro
authors.initials: T
authors.lastname: Yoshinami
authors.forename: Toshinari
authors.initials: T
authors.lastname: Yagi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Sakai
authors.forename: Naotoshi
authors.initials: N
authors.lastname: Sugimoto
authors.forename: Fumio
authors.initials: F
authors.lastname: Imamura
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary; D004164:Diphosphonates / Q000009:adverse effects*; D005198:Fanconi Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000652:urine; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D007093:Imidazoles / Q000009:adverse effects*; D007677:Kidney Function Tests; D008875:Middle Aged; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid